← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Five Eleven Pharma, Inc.
Philadelphia, PA
$1,850,935
Total funding
3
Grants
Funding over time
peak $853.1K · FY2017–20$1M$750K$500K$250K$0
'17
'18
'19
'20
Funding mix
By agency
NIH$1,850,935 · 3
By mechanism
R44$1,400,935 · 1
R43$450,000 · 2
Investigators at Five Eleven Pharma, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Commercialization of a proprietary Ga-68 PSMA-targeted drug for PET imaging in recurrent prostate cancer$853,093
R44 · FY2019 · CA
Commercialization of a proprietary Ga-68 PSMA-targeted drug for PET imaging in recurrent prostate cancer$299,412
R44 · FY2018 · CA
Commercialization of a proprietary Ga-68 PSMA-targeted drug for PET imaging in recurrent prostate cancer$248,430
R44 · FY2020 · CA
Development of novel gallium-68 bisphosphonate for imaging bone metastases in prostate cancer$225,000
R43 · FY2017 · CA
A low-cost automated Gallium-68 drug preparation device for diagnostic PET imaging$225,000
R43 · FY2017 · CA